Q-omics provides the consensus-scored BAP1 profile across patient tissues and cancer cell-line models. BAP1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BAP1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, BAP1 RNA expression shows 19,596 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where BAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BAP1 survival associations across molecular data types. BAP1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BAP1 RNA expression–survival associations across cancer types. High BAP1 expression shows unfavorable associations in ACC and LIHC, but favorable associations in UVM, THYM, KIRC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for BAP1 RNA expression.
This table summarizes BAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BAP1 shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, LIHC, COAD and STAD. The HNSC box plot shows higher BAP1 RNA expression in tumor versus normal tissue (log2 FC = +0.472, t-test p < 0.001).
This table shows molecular features associated with BAP1 in patient tissues and cancer cell lines. In patient samples, BAP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BAP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
